Evidence map›Paper›PMID 38375361›Full record

ReviewFrontiers in cellular and infection microbiology2024

Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1.

Ahmed Magdy Khalil, Aitor Nogales, Luis Martínez-Sobrido, Ahmed Mostafa

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The Therapeutic Administration ofMicroorganisms · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Ahmed Magdy Khalil *Disease Intervention & Prevention and Host Pathogen Interactions Programs, Texas Biomedical Research Institute, San Antonio, TX, United States.
Aitor Nogales *Center for Animal Health Research, CISA-INIA-CSIC, Madrid, Spain.
Luis Martínez-SobridoDisease Intervention & Prevention and Host Pathogen Interactions Programs, Texas Biomedical Research Institute, San Antonio, TX, United States.
Ahmed MostafaDisease Intervention & Prevention and Host Pathogen Interactions Programs, Texas Biomedical Research Institute, San Antonio, TX, United States.
Texas Biomedical Research Institute · US

Funding

Development of a High-Throughput Microfluidics-Enabled Functional Assay for Rapidly Identifying Neutralizing AntibodiesR01AI141607 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI DE FIGUEIREDO, PAUL, HAN, ARUM · 2019 to 2023
$3.4M
Mechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-2R01AI161363 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GUPTA, YOGESH K · 2021 to 2025
$3.2M
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell responseR01AI145332 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2019 to 2022
$3.0M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus BiologyR01AI142985 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI DE LA TORRE, JUAN C., MARTINEZ-SOBRIDO, LUIS · 2019 to 2022
$1.8M
Developing a Thermostable SARS-CoV-2 RBD-particle VaccineR43AI165089 · NIAID · POP BIOTECHNOLOGIES, INC · PI HUANG, WEI-CHIAO · 2021 to 2022
$600k
Novel animal models to study organ-specific SARS-CoV-2-induced pathologyR21AI173816 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KOROLEVA, EKATERINA, MARTINEZ-SOBRIDO, LUIS · 2023 to 2024
$499k
NIAID NIH HHS R01 AI141607NIAID NIH HHS R01 AI142985NIAID NIH HHS R01 AI145332NIAID NIH HHS R01 AI161175NIAID NIH HHS R01 AI161363NIAID NIH HHS R21 AI173816NIAID NIH HHS R43 AI165089
6 · The paper itself

Abstract

Following virus recognition of host cell receptors and viral particle/genome internalization, viruses replicate in the host via hijacking essential host cell machinery components to evade the provoked antiviral innate immunity against the invading pathogen. Respiratory viral infections are usually acute with the ability to activate pattern recognition receptors (PRRs) in/on host cells, resulting in the production and release of interferons (IFNs), proinflammatory cytokines, chemokines, and IFN-stimulated genes (ISGs) to reduce virus fitness and mitigate infection. Nevertheless, the game between viruses and the host is a complicated and dynamic process, in which they restrict each other via specific factors to maintain their own advantages and win this game. The primary role of the non-structural protein 1 (NS1 and Nsp1) of influenza A viruses (IAV) and the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respectively, is to control antiviral host-induced innate immune responses. This review provides a comprehensive overview of the genesis, spatial structure, viral and cellular interactors, and the mechanisms underlying the unique biological functions of IAV NS1 and SARS-CoV-2 Nsp1 in infected host cells. We also highlight the role of both non-structural proteins in modulating viral replication and pathogenicity. Eventually, and because of their important role during viral infection, we also describe their promising potential as targets for antiviral therapy and the development of live attenuated vaccines (LAV). Conclusively, both IAV NS1 and SARS-CoV-2 Nsp1 play an important role in virus-host interactions, viral replication, and pathogenesis, and pave the way to develop novel prophylactic and/or therapeutic interventions for the treatment of these important human respiratory viral pathogens.

Indexed as

COVID-19Influenza A virusHumansImmunity, InnateInterferonsSARS-CoV-2Virus ReplicationInterferonsantiviralsinfluenza A virusinnate immunitylive attenuated vaccinesnon-structural protein 1NS1Nsp1SARS-CoV-2

Identifiers

PMID38375361
PMCPMC10875036
OpenAlexW4391536573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.